Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 7/20 | 0.33 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318355 | 1.00 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1964905 | 1.00 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27764226 | 0.85 | CYP2D6 (0.37) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2331892 | 0.84 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL31301962 | 0.84 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28836831 | 0.84 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16449787 | 0.84 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL31698005 | 0.84 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL26765471 | 0.83 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7328149 | 0.83 | CYP2D6 (0.49) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110525-B2 | Method for enzymatic preparation of R-3 aminobutyric acid | Abiochem Biotechnology (Group) Co., Ltd. (CN) | 2024-10-08 | — | — | US | disclosed |
| CN-113286792-B | N-chromen-4-one containing derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023179366-A1 | OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 星希尔生物科技(上海)有限公司 | 2023-09-28 | — | — | WO | disclosed |
| EP-3894402-B1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2023-07-05 | — | — | EP | disclosed |
| US-20230102309-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | Ascendis Pharma Oncology Division A/S (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| CN-109576317-B | Method for preparing R-3-aminobutyric acid by enzyme method | 弈柯莱(台州)药业有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20220169639-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| CN-112725322-B | Aspartase mutant, coding gene and engineering bacterium | 天津大学 | 2022-05-10 | — | — | CN | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| CN-1227248-C | Imidazolidine derivatives, their preparation, and their use as antinflamatory agent | AVENTIS PHARMA GMBH (DE) | 2005-11-16 | — | — | CN | disclosed |
| WO-2005095395-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| CN-1221535-C | Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA GMBH (DE) | 2005-10-05 | — | — | CN | disclosed |
| CN-1537000-A | Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists | ������ҽҩ�¹�����˾ | 2004-10-13 | — | — | CN | disclosed |
| CN-1496360-A | Imidazolidine derivatives, their preparation, and their use as antinflamatory agent | ������ҽҩ�¹�����˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1484645-A | Novel beta-lactam compound and process for producing the same | ס����ҩ��ʽ���� | 2004-03-24 | — | — | CN | disclosed |
| CN-1356986-A | Spiroimidazolidine derivatives, their prepn. their use and pharmaceutical prepns. comprising them | AVENTIS PHARMA GMBH (DE) | 2002-07-03 | — | — | CN | disclosed |
| CN-1225360-A | Substituted imidazolidine derivatives, their prepn., their use and pharmaceutical prepn. comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-08-11 | — | — | CN | disclosed |
| EP-0400290-A1 | 5-Amino-4-hydroxyvalerianic acid derivatives useful as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169639-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR0B1, CYP7A1 | CYP2D6 165/4885HDAC3 1290/4885HDAC1 1284/4885 |
| US-20230102309-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | ABL1, ERBB2, ROS1 | CYP2D6 1667/4885HDAC3 1150/4885HDAC1 569/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | CYP2D6 5/4885HDAC3 1162/4885HDAC1 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.